9） Abecasis GR, Altshuler D, Auton A, Brooks L, Durbin RM, Gibbs RA, et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467(7319): 1061-73.10） Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis E, Schaffner SF, Yu F, et al. Integrating common and rare genetic variation in diverse human populations. Nature 2010; 467(7311): 52-8.11） Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81(3): 559-75.12） Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 2001; 46(8): 471-7.13） Encalada Ventura MA, van Wanrooy MJ, Span LF, Rodgers MGG, van dan Heuvel ER, Uges DRA, et al. Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations. Antimicrob Agents Chemother 2016; 60(5): 2727-31.14） Ter Avest M, Veringa A, van den Heuvel ER, Kosterink JG, Shölvinck EH, Tissing WJ, et al. The effect of inflammation on voriconazole trough concentrations in children. Br J Clin Pharmacol 2017; 83(3): 678-80.15） Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003; 31(5): 540-7.1161） 抗菌薬TDM臨床実践ガイドライン2022.2） Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther 2017; 102(1): 45-51.3） Barbarino JM, Owusu Obeng A, Klein TE, Altman RB. PharmGKB summary: voriconazole pathway, pharmacokinetics. Pharmacogenet Genomics 2017; 27(5): 201-9.4） Hicks JK, Crews KR, Flynn P, Haidar CE, Daniels CC, Yang W, et al. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics 2014; 15(8): 1065-78.5） Teusink A, Vinks A, Zhang K, Davies S, Fukuda T, Lane A, et al. Genotype-directed dosing leads to optimized voriconazole levels in pediatric patients receiving hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2016; 22(3): 482-6.6） Gautier-Veyret E, Truffot A, Bailly S, Fonrose X, Thiebaut-Bertrand A, Tonini J, et al. Inflammation is a potential risk factor of voriconazole overdose in hematological patients. Fundam Clin Pharmacol 2019; 33(2): 232-8.7） He HR, Sun JY, Ren XD, Wong TT, Zhai YJ, Chen SY, et al. Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole. Eur J Clin Microbiol Infect Dis 2015; 34(4): 811-9.8） Duflot T, Schrapp A, Bellien J, Lamoureux F. Impact of CYP3A4 genotype on voriconazole exposure. Clin Pharmacol Ther 2018; 103(2): 185-6.文 献
元のページ ../index.html#130